#United States #Palo Alto #Evommune #EVO756 #Chronic Urticaria

Evommune's Phase 2 Results for EVO756 in Chronic Inducible Urticaria

Evommune, Inc., a pioneering biotechnology firm focused on chronic inflammatory diseases, revealed promising results from their Phase 2 clinical trial for EVO756, an oral inhibitor designed to target MRGPRX2, a receptor linked to inflammatory responses. The detailed findings were presented at the European Academy of Dermatology and Venereology (EADV) 2025 Congress held in Paris, which marked a significant milestone for the company and the medical community.

Key Findings of the Trial

The trial's results demonstrated that an impressive 93% of participants experienced noticeable clinical responses just four weeks into the treatment. Improvements were recorded in various measures of itch severity, with effects observed as early as one week post-initiation of the therapy.

Dosing and Response Rates

Participants of the trial were administered EVO756 at either 300 mg once daily or 50 mg twice daily. Notably, 70% of patients reported improvements in their FricTest Score—an evaluation of skin reaction to pressure—within the same four-week period. Equally promising was the fact that 30% achieved a complete response, a remarkable outcome indicating the potential of this treatment in managing chronic inducible urticaria (CIndU).

Furthermore, the data showed that 78% of participants reported reduced itch as measured by the Pruritus Numeric Rating Scale (NRS). A remarkable 41% exhibited at least a 4-point reduction, highlighting the efficacy of EVO756 as a fast-acting treatment.

Safety Profile

In tandem with its efficacy, EVO756 demonstrated a favorable safety profile consistent with earlier Phase 1 studies, where no serious adverse events were reported during the trial. This outcome is pivotal, as it reflects the potential for broad applicability of the treatment without imposing additional health risks on individuals with chronic urticaria.

Clinical Implications

Edward (Ted) Lain, M.D., M.B.A., a dermatology specialist and investigator, stated, “The full Phase 2 data presented today highlight EVO756's dual mechanism targeting mast cells, showing encouraging results. If approved, EVO756 could offer a significant alternative to existing biologics and other treatment strategies.”

These findings also resonate with the ongoing quest for more effective treatments for chronic spontaneous urticaria (CSU) and allergic conditions like atopic dermatitis (AD). The mechanisms of EVO756 indicate a promising pathway toward ameliorating underlying causes of inflammation and itch associated with these conditions.

Next Steps

Looking ahead, Evommune anticipates sharing findings from ongoing Phase 2b trials focusing on CSU and AD, with data expected to surface by early 2026 for CSU and later that year for AD. This chronology of results underscores the company's commitment to pushing the boundaries of current therapeutic options and fulfilling unmet medical needs in the arena of chronic inflammatory diseases.

Dr. J. Mark Jackson, Vice President of Clinical Development at Evommune, expressed optimism about the new potential therapeutic approach that EVO756 represents. Targeting MRGPRX2 not only opens avenues for innovative treatments in skin-related conditions but also addresses broader implications in managing neurogenic inflammation.

Conclusion

Wholly, the Phase 2 results for EVO756 represent a noteworthy advancement in clinical research surrounding chronic urticaria. As the medical community continues to seek solutions for managing chronic inflammatory diseases, Evommune's dedicated efforts signal a bright future for patients grappling with these conditions. The compelling data presented at EADV 2025 sets a strong precedent for the need for innovation in this field, holding promise for improved quality of life for those suffering from chronic itch and related disorders.

For further details on the ongoing developments and results, Evommune has made an on-demand webinar available on their website, providing deeper insights into this groundbreaking research.

About Evommune, Inc.

Evommune is a clinical-stage biotechnology company focused on innovating therapies targeting the underlying drivers of chronic inflammatory diseases. With its mission to enhance patient lives and reduce the consequences of uncontrolled inflammation, Evommune seeks to advance a portfolio of differentiated therapies that can meet the rising demands of patients in need of effective treatments.